Amlodipine Besylate
Product Images NDC 53808-1029

4 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 53808-1029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 5mg (Qualitest)

Label Image For 5mg (Qualitest)
The label for Amlodipine Besylate 5 mg tablets shows a quantity of 30 tablets. It is marked as prescription only and manufactured by the State of Florida DOH Central Pharmacy in Tallahassee, FL 32304. The label includes lot and expiration dates and a UPC barcode.*
FDA Label Image

This Is An Image Of The Structural Formula For Amlodipine Besylate. (Amlodusp 1)

This Is An Image Of The Structural Formula For Amlodipine Besylate. (Amlodusp 1)
Chemical structure of Amlodipine Besylate showing its molecular components and bonds, including a chlorophenyl group and ester functional groups.*
FDA Label Image

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)
A Kaplan-Meier survival curve chart comparing event rates over time in months for Amlodipine and Placebo groups. The x-axis shows time from 0 to 24 months with number at risk indicated, and the y-axis shows event rate ranging from 0 to 0.25. Amlodipine group has a consistently lower event rate versus Placebo. Statistical summary with p-value, hazard ratio, and 95% confidence interval is shown in a box.*
FDA Label Image

Figure 2 (Effects on Primary Endpoint of Amlodipine versus Placebo across Sub-Groups)

Figure 2 (Effects on Primary Endpoint of Amlodipine versus Placebo across Sub-Groups)
A forest plot displaying hazard ratios with 95% confidence intervals comparing Amlodipine versus placebo across various patient subgroups, including overall population, age groups (<65, ≥65), gender, baseline sitting systolic blood pressure, baseline vessel disease, baseline vessels with stenosis, and PCI-stent strata. The x-axis represents hazard ratio values from 0.0 to 2.0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.